| scholarly article | Q13442814 |
| P50 | author | Phoebe C M Williams | Q80179733 |
| James Berkley | Q47503663 | ||
| P2093 | author name string | Phoebe C M Williams | |
| P2860 | cites work | Molecular characterization of the extended-spectrum beta-lactamase (ESBL)-producing Shigella spp. in Shanghai | Q85634678 |
| Antibiotic therapy for Shigella dysentery | Q24236428 | ||
| Azithromycin and the risk of cardiovascular death | Q24604355 | ||
| Characteristics of Multidrug Resistant Shigella and Vibrio cholerae O1 Infections in Patients Treated at an Urban and a Rural Hospital in Bangladesh | Q40166060 | ||
| Azithromycin plus artesunate versus artemether-lumefantrine for treatment of uncomplicated malaria in Tanzanian children: a randomized, controlled trial. | Q40379336 | ||
| Treatment of shigellosis with cefixime: two days vs. five days | Q40619200 | ||
| Importation and domestic transmission of Shigella sonnei resistant to ciprofloxacin - United States, May 2014-February 2015. | Q41120581 | ||
| Azithromycin/chloroquine combination does not increase cardiac instability despite an increase in monophasic action potential duration in the anesthetized guinea pig. | Q41941966 | ||
| Ciprofloxacin-Resistant Shigella sonnei Associated with Travel to India | Q42584791 | ||
| Reduced azithromycin susceptibility in Shigella sonnei, United States | Q42972710 | ||
| Molecular characterization of ESBL-producing Shigella sonnei isolates from patients with bacilliary dysentery in Lebanon. | Q43275646 | ||
| QT prolongation associated with azithromycin/amiodarone combination | Q43798312 | ||
| Peripheral neuropathy and Guillain-Barré syndrome risks associated with exposure to systemic fluoroquinolones: a pharmacovigilance analysis | Q43846018 | ||
| Single dose of azithromycin or three-day course of ciprofloxacin as therapy for epidemic dysentery in Kenya. Acute Dysentery Study Group | Q44394202 | ||
| A randomized, double-blind study comparing cefixime and trimethoprim-sulfamethoxazole in the treatment of childhood shigellosis. | Q54227510 | ||
| Nationwide dissemination of multiply resistant Shigella sonnei following a common-source outbreak. | Q54398835 | ||
| Azithromycin Can Prolong QT Interval and Suppress Ventricular Contraction, but Will Not Induce Torsade de Pointes | Q59152991 | ||
| Shigella dysenteriae type 1--Guatemala, 1991 | Q70181091 | ||
| Antibiotics for the treatment of dysentery in children | Q24613293 | ||
| Antibiotics for the treatment of Cholera, Shigella and Cryptosporidium in children | Q27009922 | ||
| Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study | Q28005554 | ||
| A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology | Q28767862 | ||
| GRADE guidelines: 3. Rating the quality of evidence | Q29547891 | ||
| Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study | Q30275836 | ||
| Practice guidelines for the management of infectious diarrhea | Q30306770 | ||
| Enterohaemorrhagic Escherichia coli and Shigella dysenteriae type 1-induced haemolytic uraemic syndrome | Q33379683 | ||
| Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports | Q33695227 | ||
| Global burden of Shigella infections: implications for vaccine development and implementation of control strategies | Q33749510 | ||
| Standards for CHERG reviews of intervention effects on child survival | Q33754532 | ||
| Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition | Q33834603 | ||
| A multi-center randomized trial to assess the efficacy of gatifloxacin versus ciprofloxacin for the treatment of shigellosis in Vietnamese children | Q33988931 | ||
| Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval | Q34298973 | ||
| Epidemic and virulence characteristic of Shigella spp. with extended-spectrum cephalosporin resistance in Xiaoshan District, Hangzhou, China | Q34501014 | ||
| Comparative safety of artemether-lumefantrine and other artemisinin-based combinations in children: a systematic review | Q35029488 | ||
| Comparison of azithromycin plus chloroquine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in children in Africa: a randomized, open-label study | Q35175033 | ||
| Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania | Q35519260 | ||
| Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency | Q35653211 | ||
| Shigella infections in children: new insights | Q35923388 | ||
| Efficacy and Safety of Azithromycin-Chloroquine versus Sulfadoxine-Pyrimethamine for Intermittent Preventive Treatment of Plasmodium falciparum Malaria Infection in Pregnant Women in Africa: An Open-Label, Randomized Trial | Q36057593 | ||
| Shigellosis with decreased susceptibility to azithromycin | Q36429066 | ||
| Clinical implications of reduced susceptibility to fluoroquinolones in paediatric Shigella sonnei and Shigella flexneri infections | Q36551331 | ||
| Antimicrobial-associated QT interval prolongation: pointes of interest | Q36655034 | ||
| Prevalence and trends of aminoglycoside resistance in Shigella worldwide, 1999-2010. | Q36700457 | ||
| Comparison of the prevalence and changing resistance to nalidixic acid and ciprofloxacin of Shigella between Europe-America and Asia-Africa from 1998 to 2009. | Q38000763 | ||
| Azithromycin-induced proarrhythmia and cardiovascular death | Q38167011 | ||
| Comparison of resistance to third-generation cephalosporins in Shigella between Europe-America and Asia-Africa from 1998 to 2012. | Q38305664 | ||
| Oral fluoroquinolone use and risk of peripheral neuropathy: a pharmacoepidemiologic study | Q38419133 | ||
| Randomized comparison of azithromycin versus cefixime for treatment of shigellosis in children | Q38896437 | ||
| Comparison of the efficacy, safety and cost of cefixime, ceftriaxone and aztreonam in the treatment of multidrug-resistant Salmonella typhi septicemia in children | Q39024524 | ||
| Etiological diversity of diarrhoeal disease in Bangladesh | Q40157592 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | sup1 | |
| P921 | main subject | shigellosis | Q327298 |
| P304 | page(s) | S50-S65 | |
| P577 | publication date | 2018-11-01 | |
| P1433 | published in | Paediatrics and international child health | Q26867049 |
| P1476 | title | Guidelines for the treatment of dysentery (shigellosis): a systematic review of the evidence | |
| P478 | volume | 38 |
| Q64903335 | Antimicrobial susceptibility profile & resistance mechanisms of Global Antimicrobial Resistance Surveillance System (GLASS) priority pathogens from India. |
| Q92368044 | Characterizing Shigella species distribution and antimicrobial susceptibility to ciprofloxacin and nalidixic acid in Latin America between 2000-2015 |
| Q93167721 | Childhood diarrhoeal diseases in developing countries |
| Q88782797 | Empirical antibiotic treatment for children suffering from dysentery, cholera, pneumonia, sepsis or severe acute malnutrition |
| Q93272870 | Evidence of Failure of Oral Third-Generation Cephalosporin Treatment for Shigella sonnei Infection |
| Q93221231 | Genetic Mechanisms behind the Spread of Reduced Susceptibility to Azithromycin in Shigella Strains Isolated from Men Who Have Sex with Men in Québec, Canada |
| Q64880529 | Multidrug-resistant Shigella infection in pediatric patients with diarrhea from central Iran. |
| Q92968788 | Shigella-mediated immunosuppression in the human gut: subversion extends from innate to adaptive immune responses |
Search more.